EcoDrugPlus

Neuromedin-K Receptor-Like

Ensembl ID : ENSSTUG00000051090
Gene Symbol: LOC115153464
3 Cross references
190 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSSTUG00000048533
Gene Symbol: LOC115191930
3 Cross references
242 Possible Orthologues:

Neuromedin-K Receptor-Like

Ensembl ID : ENSSTUG00000031201
Gene Symbol: LOC115202120
3 Cross references
242 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-4-Like

Ensembl ID : ENSSTUG00000039342
Gene Symbol: LOC115166074
3 Cross references
191 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSSTUG00000027216
Gene Symbol: LOC115197124
2 Cross references
183 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSSTUG00000003170
Gene Symbol: LOC115203520
3 Cross references
204 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Alpha-7-Like

Ensembl ID : ENSSTUG00000035766
Gene Symbol: LOC115166808
3 Cross references
202 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Beta-4-Like

Ensembl ID : ENSSTUG00000010872
Gene Symbol: LOC115203017
2 Cross references
186 Possible Orthologues:

Neuronal Acetylcholine Receptor Subunit Beta-4-Like

Ensembl ID : ENSSTUG00000014619
Gene Symbol: LOC115192864
2 Cross references
125 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSTUG00000045765
Gene Symbol: NPY2R
1 Cross references
178 Possible Orthologues:

Neuropeptide Y Receptor Y2

Ensembl ID : ENSSTUG00000034390
Gene Symbol: NPY2R
3 Cross references
178 Possible Orthologues:

Neurotensin Receptor 1

Ensembl ID : ENSSTUG00000035008
Gene Symbol: NTSR1
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).